Hennion & Walsh Asset Management Inc. Acquires 19,579 Shares of Celcuity, Inc. $CELC

Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Celcuity, Inc. (NASDAQ:CELC) by 11.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 190,933 shares of the company’s stock after purchasing an additional 19,579 shares during the period. Celcuity accounts for 0.7% of Hennion & Walsh Asset Management Inc.’s holdings, making the stock its 23rd biggest holding. Hennion & Walsh Asset Management Inc. owned about 0.41% of Celcuity worth $19,044,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Apis Capital Advisors LLC bought a new stake in shares of Celcuity in the 3rd quarter valued at about $38,334,000. UBS Group AG raised its stake in Celcuity by 910.1% during the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock worth $42,211,000 after buying an additional 769,891 shares during the last quarter. Deerfield Management Company L.P. acquired a new position in Celcuity in the third quarter valued at $36,236,000. Alliancebernstein L.P. lifted its holdings in Celcuity by 2,208.6% in the third quarter. Alliancebernstein L.P. now owns 652,649 shares of the company’s stock valued at $32,241,000 after buying an additional 624,379 shares during the period. Finally, Soleus Capital Management L.P. boosted its position in Celcuity by 17.0% during the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after acquiring an additional 437,696 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

Analyst Ratings Changes

CELC has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Jefferies Financial Group boosted their target price on shares of Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a research report on Tuesday, December 2nd. Wells Fargo & Company initiated coverage on shares of Celcuity in a report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price target for the company. Stifel Nicolaus increased their price objective on shares of Celcuity from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Wolfe Research restated an “outperform” rating and issued a $110.00 target price on shares of Celcuity in a research note on Thursday, March 12th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $109.88.

Insider Buying and Selling at Celcuity

In other news, Director David Dalvey sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the completion of the transaction, the director directly owned 90,000 shares of the company’s stock, valued at $10,802,700. This represents a 18.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 15.78% of the stock is owned by insiders.

Celcuity Price Performance

CELC opened at $106.02 on Monday. Celcuity, Inc. has a fifty-two week low of $7.57 and a fifty-two week high of $120.32. The firm has a market capitalization of $5.13 billion, a P/E ratio of -27.97 and a beta of 0.38. The company’s 50-day moving average is $109.49 and its 200 day moving average is $91.20. The company has a debt-to-equity ratio of 3.20, a current ratio of 10.55 and a quick ratio of 10.55.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.09. Research analysts expect that Celcuity, Inc. will post -2.62 earnings per share for the current fiscal year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.